Predictors of overall survival
| Predictor . | Univariate . | Multivariate . | ||
|---|---|---|---|---|
| Hazard ratio . | P value . | Hazard ratio . | P value . | |
| Age (years) | 1.01 (0.98-1.04) | .511 | ||
| Gender (female) | 1.05 (0.54-2.03) | .874 | ||
| Underlying disease (leukemia vs other) | 1.11 (0.57-2.14) | .763 | ||
| Pretransplant comorbidity (HCT-CI >3) | 2.18 (1.08-4.26) | .030 | 1.42 (0.68-2.88) | .339 |
| Disease risk* | ||||
| Low | 1.0 | — | 1.0 | — |
| Intermediate | 2.39 (0.97-6.19) | .059 | 4.17 (1.55-11.68) | .005 |
| High | 1.47 (0.65-3.62) | .357 | 2.04 (0.87-5.18) | .103 |
| Conditioning intensity | ||||
| Nonmyeloablative | 1.0 | — | ||
| Reduced intensity | 1.89 (0.71-5.89) | .209 | ||
| Myeloablative | 1.62 (0.64-4.91) | .324 | ||
| Stem cell source | ||||
| Related identical sibling | 1.0 | — | ||
| Unrelated identical | 1.32 (0.58-2.98) | .500 | ||
| Unrelated nonidentical | 1.52 (0.42-4.39) | .486 | ||
| Cord blood | 1.40 (0.55-3.38) | .472 | ||
| T-cell depletion (ex vivo) | 0.92 (0.47-1.77) | .803 | ||
| Time to engraftment (≥14 d post-HSCT) | 1.10 (0.47-2.30) | .819 | ||
| Ursodeoxycholic acid† | 0.94 (0.38-2.04) | .885 | ||
| Liver dysfunction (total bilirubin > twice baseline)† | 1.55 (0.58-3.48) | .353 | ||
| Acute kidney injury (creatinine > twice baseline)† | 1.40 (0.66-2.79) | .360 | ||
| TPN† | 1.41 (0.67-3.32) | .377 | ||
| Antibiotics† | ||||
| Vancomycin (intravenous) | 2.60 (0.79-16.07) | .131 | 1.28 (0.28-9.02) | .764 |
| Fluoroquinolone‡ | 0.52 (0.21-1.12) | .100 | 0.34 (0.13-0.78) | .010 |
| Metronidazole | 1.47 (0.71-2.90) | .286 | ||
| β-lactam§ | 3.97 (1.21-24.48) | .019 | 3.22 (0.84-21.14) | .094 |
| Infections† | ||||
| C difficile infection | 0.76 (0.26-1.80) | .564 | ||
| Gram-negative bloodstream infection | 1.58 (0.59-3.55) | .331 | ||
| VRE bloodstream infection | 1.10 (0.18-3.60) | .901 | ||
| Microbial diversity (engraftment) | ||||
| High diversity (inverse Simpson >4) | 1.0 | — | 1.0 | — |
| Intermediate diversity (inverse Simpson 2-4) | 1.83 (0.65-5.22) | .245 | 1.26 (0.42-3.86) | .673 |
| Low diversity (inverse Simpson <2) | 3.13 (1.39-7.98) | .005 | 2.56 (1.03-7.23) | .042 |
| Predictor . | Univariate . | Multivariate . | ||
|---|---|---|---|---|
| Hazard ratio . | P value . | Hazard ratio . | P value . | |
| Age (years) | 1.01 (0.98-1.04) | .511 | ||
| Gender (female) | 1.05 (0.54-2.03) | .874 | ||
| Underlying disease (leukemia vs other) | 1.11 (0.57-2.14) | .763 | ||
| Pretransplant comorbidity (HCT-CI >3) | 2.18 (1.08-4.26) | .030 | 1.42 (0.68-2.88) | .339 |
| Disease risk* | ||||
| Low | 1.0 | — | 1.0 | — |
| Intermediate | 2.39 (0.97-6.19) | .059 | 4.17 (1.55-11.68) | .005 |
| High | 1.47 (0.65-3.62) | .357 | 2.04 (0.87-5.18) | .103 |
| Conditioning intensity | ||||
| Nonmyeloablative | 1.0 | — | ||
| Reduced intensity | 1.89 (0.71-5.89) | .209 | ||
| Myeloablative | 1.62 (0.64-4.91) | .324 | ||
| Stem cell source | ||||
| Related identical sibling | 1.0 | — | ||
| Unrelated identical | 1.32 (0.58-2.98) | .500 | ||
| Unrelated nonidentical | 1.52 (0.42-4.39) | .486 | ||
| Cord blood | 1.40 (0.55-3.38) | .472 | ||
| T-cell depletion (ex vivo) | 0.92 (0.47-1.77) | .803 | ||
| Time to engraftment (≥14 d post-HSCT) | 1.10 (0.47-2.30) | .819 | ||
| Ursodeoxycholic acid† | 0.94 (0.38-2.04) | .885 | ||
| Liver dysfunction (total bilirubin > twice baseline)† | 1.55 (0.58-3.48) | .353 | ||
| Acute kidney injury (creatinine > twice baseline)† | 1.40 (0.66-2.79) | .360 | ||
| TPN† | 1.41 (0.67-3.32) | .377 | ||
| Antibiotics† | ||||
| Vancomycin (intravenous) | 2.60 (0.79-16.07) | .131 | 1.28 (0.28-9.02) | .764 |
| Fluoroquinolone‡ | 0.52 (0.21-1.12) | .100 | 0.34 (0.13-0.78) | .010 |
| Metronidazole | 1.47 (0.71-2.90) | .286 | ||
| β-lactam§ | 3.97 (1.21-24.48) | .019 | 3.22 (0.84-21.14) | .094 |
| Infections† | ||||
| C difficile infection | 0.76 (0.26-1.80) | .564 | ||
| Gram-negative bloodstream infection | 1.58 (0.59-3.55) | .331 | ||
| VRE bloodstream infection | 1.10 (0.18-3.60) | .901 | ||
| Microbial diversity (engraftment) | ||||
| High diversity (inverse Simpson >4) | 1.0 | — | 1.0 | — |
| Intermediate diversity (inverse Simpson 2-4) | 1.83 (0.65-5.22) | .245 | 1.26 (0.42-3.86) | .673 |
| Low diversity (inverse Simpson <2) | 3.13 (1.39-7.98) | .005 | 2.56 (1.03-7.23) | .042 |